Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eos Energy Enterprises Inc (EOSE) vs Eli Lilly And Co (LLY) Price & Performance

Eos Energy Enterprises IncTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Eos Energy Enterprises Inc vs Eli Lilly And Co — how do they compare? Eos Energy Enterprises Inc trades at $2.83 (market cap $1.13B), while Eli Lilly And Co trades at $1,167.38 (market cap $1.06T). The key difference: Eli Lilly And Co is far larger — about 938.1× Eos Energy Enterprises Inc's market cap, and Eli Lilly And Co pays a 0.58% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Eli Lilly And Co for 93 Days on average.

EOSELLY
Market Cap
$1.13B$1.06T
Volume
17,918,7772,297,239
Sector
IndustrialsHealth
52-Week High
$19.19$1.28K
52-Week Low
$2.77$799.57
Typical Hold Time
16 Days93 Days
Enterprise Value
$1.47B$1.11T
Dividend Yield
—0.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eos Energy Enterprises Inc

Eos Energy Enterprises (EOSE) trades at $3.10, down 4.91% on the day, with a bearish technical signal from moving averages. The company is in a high-growth phase, with revenue surging from $114.20 million in 2025 to $214 million in 2026, though it remains deeply unprofitable with a net income margin of -246.76%. Recent positive developments include a major partnership with Google and a $87 million Department of Energy loan advance to expand production capacity.

The outlook is a mix of high growth potential and significant financial risk. Analyst consensus is a 'Buy' with a $7.10 price target, implying substantial upside, but the stock carries execution risk as the company burns cash to scale. Investors are betting on EOSE capturing market share in long-duration energy storage, but must tolerate volatility and ongoing losses.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,169.93, up 1.07% on the day, with a bullish technical signal and strong fundamental momentum. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $8.38 exceeding the $6.40 estimate. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Positive news flow highlights promising pipeline updates in weight-loss and diabetes drugs, reinforcing growth prospects.

Outlook remains favorable given dominant market position and innovation pipeline, though high valuation multiples pose a risk. Analyst consensus is strongly bullish with a $1,340 price target. Key risks include competitive pressures and execution challenges in scaling production to meet demand for blockbuster therapies.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EOSE
17% Buy83% Sell
Avg holding period · 16 Days
LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About Eos Energy Enterprises Inc

Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.

Read more on EOSE →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →